Targeting VEGF/VEGFR in the treatment of psoriasis

Discovery Medicine

Volumn 18, Issue 98, 2014, Pages 97-104

  Li, Wei ^a   Man, Xiao Yong ^a   Chen, Jia Qi ^a   Zhou, Jiong ^a   Cai, Sui Qing ^a   Zheng, Min ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PLACENTAL GROWTH FACTOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TANIBIRUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VEGFA PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; DERMATITIS; DISEASE SEVERITY; DRUG TARGETING; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; PSORIASIS; RNA SPLICING; SKIN DEFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DISEASE MODEL; GENETICS; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PSORIASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84933042006     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Abe R, Yamagishi S, Fujita Y, Hoshina D, Sasaki M, Nakamura K, Matsui T, Shimizu T, Bucala R, Shimizu H. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. J Dermatol Sci 57(3):183-191, 2010.
2. Akman A, Yilmaz E, Mutlu H, Ozdogan M. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 34(5):e202-e204, 2009.
3. Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol 146(2):131-139, 2013.
4. Becerra SP, Notario V. The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat Rev Cancer 13(4):258-271, 2013.
5. Bhushan M, Mclaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141(6):1054-1060, 1999.
6. Boehncke WH, Dressel D, Zollner TM, Kaufmann R. Pulling the trigger on psoriasis. Nature 379(6568):777, 1996.
7. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, Van De Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176(5):1375-1379, 1992.
8. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 9(4):302-309, 2012.
9. Canavese M, Altruda F, Ruzicka T, Schauber J. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-a possible target for novel therapies? J Dermatol Sci 58(3):171-176, 2010.
10. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298-307, 2011.
11. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63(5):601-615, 2006.
12. Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol 123(2):129-138, 2007.
13. Crow JM. Therapeutics: Silencing psoriasis. Nature 492(7429):S58-59, 2012.
14. Detmar M. Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J Invest Dermatol 122(1):xiv-xv, 2004.
15. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180(3):1141-1146, 1994.
16. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111(1):1-6, 1998.
17. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795-803, 2002.
18. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med 9(6):669-676, 2003.
19. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391-400, 2004.
20. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 370(9583):263-271, 2007.
21. Griffiths CE, Strober BE, Van De Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362(2):118-128, 2010.
22. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897-1908, 2011.
23. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19(10):2003-2012, 2007.
24. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23(5):289-304, 2009.
25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342, 2004.
26. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 82(3):673-700, 2002.
27. Kim EJ, Park HY, Yaar M, Gilchrest BA. Modulation of vascular endothelial growth factor receptors in melanocytes. Exp Dermatol 14(8):625-633, 2005.
28. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356(6):580-592, 2007.
29. Kurschat P, Bielenberg D, Rossignol-Tallandier M, Stahl A, Klagsbrun M. Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration. J Biol Chem 281(5):2721-2729, 2006.
30. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349(21):2004-2013, 2003.
31. Lee SH. Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res 34(8):1223-1226, 2011.
32. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366(13):1190-1199, 2012.
33. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21):2014-2022, 2003.
34. Li W, Lu ZF, Man XY, Li CM, Zhou J, Chen JQ, Yang XH, Wu XJ, Cai SQ, Zheng M. VEGF upregulates VEGF receptor-2 on human outer root sheath cells and stimulates proliferation through ERK pathway. Mol Biol Rep 39(9):8687-8694, 2012a.
35. Li W, Man XY, Li CM, Chen JQ, Zhou J, Cai SQ, Lu ZF, Zheng M. VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK. Exp Cell Res 318(14):1633-1640, 2012b.
36. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21(2):154-165, 2009.
37. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 445(7130):866-873, 2007.
38. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34(4):174-181, 2013.
39. Man XY, Yang XH, Cai SQ, Bu ZY, Wu XJ, Lu ZF, Zheng M. Expression and localization of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in human epidermal appendages: a comparison study by immunofluorescence. Clin Exp Dermatol 34(3):396-401, 2009.
40. Man XY, Yang XH, Cai SQ, Bu ZY, Zheng M. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med 12(2):649-660, 2008.
41. Man XY, Yang XH, Cai SQ, Yao YG, Zheng M. Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med 12(7-8):127-136, 2006.
42. Manalo KB, Choong PF, Becerra SP, Dass CR. Pigment epithelium-derived factor as an anticancer drug and new treatment methods following the discovery of its receptors: a patent perspective. Exp Opin Ther Pat 21(2):121-130, 2011.
43. Meissner M, Doll M, Hrgovic I, Reichenbach G, Konig V, Hailemariam-Jahn T, Gille J, Kaufmann R. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol 131(6):1356-1364, 2011.
44. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 361(5):496-509, 2009.
45. Ng YS, Krilleke D, Shima DT. VEGF function in vascular pathogenesis. Exp Cell Res 312(5):527-537, 2006.
46. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7(5):359-371, 2006.
47. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358(3):241-251, 2008.
48. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 380(9843):738-746, 2012a.
49. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366(13):1181-1189, 2012b.
50. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 167(3):668-677, 2012c.
51. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168(2):402-411, 2013.
52. Schon MP. Animal models of psoriasis - what can we learn from them? J Invest Dermatol 112(4):405-410, 1999.
53. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 352(18):1899-1912, 2005.
54. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci U S A 106(50):21264-21269, 2009.
55. Selheim F, Holmsen H, Vassbotn FS. Identification of functional VEGF receptors on human platelets. FEBS Lett 512(1-3):107-110, 2002.
56. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9(4):225-230; discussion 231, 2006.
57. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, Mchugh NJ, Mckenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 161(5):987-1019, 2009.
58. Spratlin J. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Reports 13(2):97-102, 2011.
59. Van Der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182(9):5836-5845, 2009.
60. Waisman A. To be 17 again-anti-interleukin-17 treatment for psoriasis. N Engl J Med 366(13):1251-1252, 2012.
61. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437(7058):497-504, 2005.
62. Wey JS, Stoeltzing O, Ellis LM. Vascular endothelial growth factor receptors: expression and function in solid tumors. Clin Adv Hematol Oncol 2(1):37-45, 2004.
63. Wilgus TA, Matthies AM, Radek KA, Dovi JV, Burns AL, Shankar R, Dipietro LA. Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol 167(5):1257-1266, 2005.
64. Williams SC. New biologic drugs get under the skin of psoriasis. Nat Med 18(5):638, 2012.
65. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102(1):161-168, 2003.
66. Yang XH, Man XY, Cai SQ, Yao YG, Bu ZY, Zheng M. Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. Biochem Biophys Res Commun 349(1):31-38, 2006.
67. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 107(4):409-417, 2001.